Barriers to achieving controlled rheumatoid arthritis in the United Arab Emirates: a cross-sectional study
To better understand the factors that affect low disease activity (DAS28 ≤ 3.2, LDA) in rheumatoid arthritis (RA) and barriers within the UAE, demographic/treatment data and DAS28 scores were collected through chart reviews of 182 consecutive RA patients seen at a private clinic in Dubai over a 2-mo...
| Main Authors: | , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
Springer Berlin Heidelberg
2017
|
| Online Access: | http://hdl.handle.net/1721.1/107693 |
| _version_ | 1826197279401312256 |
|---|---|
| author | Mahfoud, Ziyad Badsha, Humeira Moufarrej, Mira N. |
| author2 | Massachusetts Institute of Technology. Department of Biological Engineering |
| author_facet | Massachusetts Institute of Technology. Department of Biological Engineering Mahfoud, Ziyad Badsha, Humeira Moufarrej, Mira N. |
| author_sort | Mahfoud, Ziyad |
| collection | MIT |
| description | To better understand the factors that affect low disease activity (DAS28 ≤ 3.2, LDA) in rheumatoid arthritis (RA) and barriers within the UAE, demographic/treatment data and DAS28 scores were collected through chart reviews of 182 consecutive RA patients seen at a private clinic in Dubai over a 2-month period. Patients were separated into a LDA group and a group comprised of moderate (3.2 < DAS28 < 5.1) or high disease activity (DAS28 ≥ 5.1) (MHDA). We then examined variables that may be associated with LDA and re-examined the MHDA group for barriers. While 97 (53 %) of the 182 patients had achieved the treatment target of DAS28 ≤ 3.2, 85 (47 %) had MHDA. A significantly larger portion of LDA patients had been previously treated with sulfasalazine (36 in LDA vs. 14 in MHDA, P = 0.002) or was presently on biological treatments (24 vs. 9, P = 0.013). For the 85 MHDA patients, 40 (22 % of 182) exhibited resistant disease with 25 (13.7 % of 182) failing their current first tier disease-modifying anti-rheumatic drug (DMARD) treatment or combinations and 15 (8.2 % of 182) failing current anti-TNF or biologic treatment. Reasons listed were primarily socioeconomic with 40 % of the resistant disease group unable to afford biologicals and 52 % of the patient-driven preference group discontinuing DMARDs against professional advice. Going forward, emphasis on the agreement between patient and rheumatologist on treatment, specifically regarding how DMARDs help relieve symptoms and their proper use, could help reduce the percentage of MHDA patients in the UAE. |
| first_indexed | 2024-09-23T10:45:35Z |
| format | Article |
| id | mit-1721.1/107693 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T10:45:35Z |
| publishDate | 2017 |
| publisher | Springer Berlin Heidelberg |
| record_format | dspace |
| spelling | mit-1721.1/1076932022-09-30T22:47:51Z Barriers to achieving controlled rheumatoid arthritis in the United Arab Emirates: a cross-sectional study Mahfoud, Ziyad Badsha, Humeira Moufarrej, Mira N. Massachusetts Institute of Technology. Department of Biological Engineering Moufarrej, Mira N. To better understand the factors that affect low disease activity (DAS28 ≤ 3.2, LDA) in rheumatoid arthritis (RA) and barriers within the UAE, demographic/treatment data and DAS28 scores were collected through chart reviews of 182 consecutive RA patients seen at a private clinic in Dubai over a 2-month period. Patients were separated into a LDA group and a group comprised of moderate (3.2 < DAS28 < 5.1) or high disease activity (DAS28 ≥ 5.1) (MHDA). We then examined variables that may be associated with LDA and re-examined the MHDA group for barriers. While 97 (53 %) of the 182 patients had achieved the treatment target of DAS28 ≤ 3.2, 85 (47 %) had MHDA. A significantly larger portion of LDA patients had been previously treated with sulfasalazine (36 in LDA vs. 14 in MHDA, P = 0.002) or was presently on biological treatments (24 vs. 9, P = 0.013). For the 85 MHDA patients, 40 (22 % of 182) exhibited resistant disease with 25 (13.7 % of 182) failing their current first tier disease-modifying anti-rheumatic drug (DMARD) treatment or combinations and 15 (8.2 % of 182) failing current anti-TNF or biologic treatment. Reasons listed were primarily socioeconomic with 40 % of the resistant disease group unable to afford biologicals and 52 % of the patient-driven preference group discontinuing DMARDs against professional advice. Going forward, emphasis on the agreement between patient and rheumatologist on treatment, specifically regarding how DMARDs help relieve symptoms and their proper use, could help reduce the percentage of MHDA patients in the UAE. 2017-03-24T16:25:12Z 2017-03-24T16:25:12Z 2014-10 2014-06 2016-05-23T12:09:48Z Article http://purl.org/eprint/type/JournalArticle 0172-8172 1437-160X http://hdl.handle.net/1721.1/107693 Moufarrej, Mira Noura, Ziyad Mahfoud, and Humeira Badsha. “Barriers to Achieving Controlled Rheumatoid Arthritis in the United Arab Emirates: a Cross-Sectional Study.” Rheumatology International 35, no. 4 (October 15, 2014): 759–763. en http://dx.doi.org/10.1007/s00296-014-3151-7 Rheumatology International Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. Springer-Verlag Berlin Heidelberg application/pdf Springer Berlin Heidelberg Springer Berlin Heidelberg |
| spellingShingle | Mahfoud, Ziyad Badsha, Humeira Moufarrej, Mira N. Barriers to achieving controlled rheumatoid arthritis in the United Arab Emirates: a cross-sectional study |
| title | Barriers to achieving controlled rheumatoid arthritis in the United Arab Emirates: a cross-sectional study |
| title_full | Barriers to achieving controlled rheumatoid arthritis in the United Arab Emirates: a cross-sectional study |
| title_fullStr | Barriers to achieving controlled rheumatoid arthritis in the United Arab Emirates: a cross-sectional study |
| title_full_unstemmed | Barriers to achieving controlled rheumatoid arthritis in the United Arab Emirates: a cross-sectional study |
| title_short | Barriers to achieving controlled rheumatoid arthritis in the United Arab Emirates: a cross-sectional study |
| title_sort | barriers to achieving controlled rheumatoid arthritis in the united arab emirates a cross sectional study |
| url | http://hdl.handle.net/1721.1/107693 |
| work_keys_str_mv | AT mahfoudziyad barrierstoachievingcontrolledrheumatoidarthritisintheunitedarabemiratesacrosssectionalstudy AT badshahumeira barrierstoachievingcontrolledrheumatoidarthritisintheunitedarabemiratesacrosssectionalstudy AT moufarrejmiran barrierstoachievingcontrolledrheumatoidarthritisintheunitedarabemiratesacrosssectionalstudy |